GlassScriptPhysician profile
Ryan Y Tsuda
NPI 1528289113
$14,063.04
in general payments reported to CMS, 2019-2025
26 companies · $2,990 in 2025
The $2,990 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,979 · 2020: $2,051 · 2021: $2,172 · 2022: $1,350 · 2023: $1,186 · 2024: $2,336 · 2025: $2,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,867 · Travel and Lodging: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,867.04 |
| Travel and Lodging | $645.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $6,211.87 | 2019-2025 | Impella |
| Medtronic, INC. | $2,215.62 | 2021-2025 | Corevalve Evolut R, Resolute Onyx, Symplicity G3 |
| Medtronic Vascular, INC. | $1,388.34 | 2019-2020 | |
| Abbott Laboratories | $1,322.48 | 2019-2025 | Mitraclip, Triclip, Xience Skypoint |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $773.75 | 2021-2025 | Lifevest |
| Inari Medical, INC. | $373.02 | 2020-2021 | |
| Boston Scientific Corporation | $273.74 | 2022-2025 | Watchman Access System, Watchman Flx |
| Acist Medical Systems, INC. | $241.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $202.62 | 2024-2025 | |
| Penumbra, INC. | $162.31 | 2025 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.65 | 2025 | Jardiance |
| Terumo Medical Corporation | $140.28 | 2021-2025 | Glidewire, Metacross Otw |
| Edwards Lifesciences Corporation | $137.31 | 2024 | Pascal |
| Recor Medical INC | $106.88 | 2024 | Paradise Renal Denervation System |
| Asahi Intecc USA, INC. | $74.47 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $41.59 | 2025 | Coronary Other |
| W. L. Gore & Associates, INC. | $32.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.38 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $30.37 | 2025 | Repatha |
| Kestra Medical Technology Services, INC. | $29.48 | 2025 | Assure Wcd |
| B. Braun Interventional Systems INC. | $28.78 | 2025 | Asept |
| Cvrx, INC. | $27.15 | 2025 | Barostim Neo System |
| Novo Nordisk INC | $24.87 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $22.59 | 2025 | |
| Baxter Healthcare | $14.16 | 2025 | Hillrom - Carnation Ambulatory Monitor |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Tsuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.